These data suggested a potential link between hepatic apoA5 retention and lipid accumulation due to olanzapine, which can promote NAFLD pathogenesis in schizophrenia patients. The gene discussed is APOA5; the disease is metabolic dysfunction-associated steatotic liver disease.